Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Twist Bioscience Corp’s stock clocked out at $42.71, down -2.87% from its previous closing price of $43.97. In other words, the price has decreased by -$2.87 from its previous closing price. On the day, 0.79 million shares were traded. TWST stock price reached its highest trading level at $43.82 during the session, while it also had its lowest trading level at $42.25.
Ratios:
To gain a deeper understanding of TWST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.91. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on June 04, 2024, initiated with a Buy rating and assigned the stock a target price of $53.
On January 17, 2024, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $25 to $45.
On September 27, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $27.Berenberg initiated its Buy rating on September 27, 2023, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 06 ’24 when Banyai William bought 1,176 shares for $45.30 per share.
Leproust Emily M. bought 5,139 shares of TWST for $205,179 on Aug 05 ’24. On Aug 05 ’24, another insider, Finn Patrick John, who serves as the Officer of the company, bought 2,885 shares for $39.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 2576023808 and an Enterprise Value of 2299968256. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.48 while its Price-to-Book (P/B) ratio in mrq is 5.09. Its current Enterprise Value per Revenue stands at 7.791 whereas that against EBITDA is -14.681.
Stock Price History:
The Beta on a monthly basis for TWST is 1.82, which has changed by 0.99953187 over the last 52 weeks, in comparison to a change of 0.20427191 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $60.90, while it has fallen to a 52-week low of $14.42. The 50-Day Moving Average of the stock is -15.61%, while the 200-Day Moving Average is calculated to be 14.73%.
Shares Statistics:
It appears that TWST traded 1.12M shares on average per day over the past three months and 1349720 shares per day over the past ten days. A total of 57.56M shares are outstanding, with a floating share count of 56.09M. Insiders hold about 4.27% of the company’s shares, while institutions hold 106.41% stake in the company. Shares short for TWST as of 1721001600 were 9530323 with a Short Ratio of 8.77, compared to 1718323200 on 10847285. Therefore, it implies a Short% of Shares Outstanding of 9530323 and a Short% of Float of 21.270001.
Earnings Estimates
The current rating of Twist Bioscience Corp (TWST) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.44 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$2.87 and -$3.76 for the fiscal current year, implying an average EPS of -$3.55. EPS for the following year is -$2.39, with 11.0 analysts recommending between -$1.97 and -$2.76.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $82.2M. It ranges from a high estimate of $83.6M to a low estimate of $78M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $66.95MFor the next quarter, 10 analysts are estimating revenue of $85.27M. There is a high estimate of $91.27M for the next quarter, whereas the lowest estimate is $81M.
A total of 11 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $312M, while the lowest revenue estimate was $310.2M, resulting in an average revenue estimate of $311.01M. In the same quarter a year ago, actual revenue was $245.11MBased on 11 analysts’ estimates, the company’s revenue will be $373.17M in the next fiscal year. The high estimate is $400.37M and the low estimate is $352M.
